There are 2949 resources available
LBA77 - Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study
Presenter: Antonio Marra
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
1671MO - Provision of palliative care for patients with cancer and SARS-CoV-2 infection
Presenter: Gehan Soosaipillai
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
1672MO - "DOMONCOVID PROJECT": A homecare model for cancer patients during COVID-19
Presenter: Margherita Ratti
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
LBA78 - A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden
Presenter: Aurelie Bardet
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
LBA79 - Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study
Presenter: Karlijn de Joode
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
LBA80 - Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
Presenter: Markus Joerger
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
1673MO - The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management
Presenter: Astrid LIÈVRE
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast
812MO - Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
Presenter: Nicoletta Colombo
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
814MO - Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Presenter: Yvette Drew
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
815MO - The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
Presenter: Benoit You
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast